Panelists discuss the INSEMA trial, comparing no axillary surgery versus axillary sentinel lymph node biopsy (SLNB) in patients with early invasive breast cancer, exploring the implications for ...

Omitting sentinel lymph node biopsy is “suitable” for certain patients with early invasive breast cancer undergoing breast-conserving surgery, according to Toralf Reimer, MD, PhD.

However, at present its role is controversial, as some groups recommend avoiding axillary lymph node dissection (ALND) in cases with metastasis of any size in the sentinel lymph nodes. Molecular ...

replace axillary dissection with sentinel [lymph] node biopsy [SLNB], give less radiotherapy in the form of partial breast irradiation or give it over a shorter period of time with ...

Omission of surgical axillary staging is noninferior to sentinel-lymph-node biopsy for patients with clinically node-negative, T1 or T2 invasive breast cancer, according to a study published ...

Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.

Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear. In this prospective, randomized, noninferiority trial, we ...

Opens in a new tab or window SAN ANTONIO -- Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent sentinel lymph node biopsy ...